Testosterone Therapy and Sexual Health in Men and Women: Is There a Role for Long-Acting Subcutaneous Pellets?
Testosterone influences sexual desire and sexual response in men and women, but the clinical reasons for prescribing it differ between the sexes. In men, treatment is reserved for symptomatic hypogonadism confirmed by repeated morning measurements, and placebo-controlled trials show improvements in libido and sexual activity, with smaller and less consistent effects on erectile function. In women, the indication with the strongest support is hypoactive sexual desire disorder after menopause, where randomized trials of transdermal testosterone show moderate gains in desire, arousal, orgasm, and satisfaction, along with less sexual distress. Subcutaneous testosterone pellets release the hormone for several months after a single office procedure and appeal to patients who prefer infrequent dosing. Most of the evidence for testosterone therapy, however, comes from transdermal and injectable preparations. Pellet studies in men describe steady release, a predictable duration of action, extrusion as the most frequent complication, and erythrocytosis that cannot be corrected by lowering the dose once the pellets are in place. The few randomized comparisons of pellets with other formulations were small, did not include transdermal testosterone, and were not designed around validated sexual-function outcomes. In women, pellets are used off-label, are often compounded, and can produce serum concentrations well above the female physiological range; current professional guidance advises against their use for hypoactive sexual desire disorder. This narrative review describes the physiology of testosterone in both sexes, the diagnostic criteria and validated instruments used to assess sexual function, the trial evidence for testosterone therapy, and the pharmacology, effectiveness, and safety of pellets. Pellets are a reasonable option for selected hypogonadal men who do not seek fertility, accept a formulation that cannot be quickly reversed, and agree to hematocrit monitoring. In women, current guidance does not support their use, and any exception requires informed consent, close monitoring, and acknowledgment that it departs from that guidance.
Authors
- Julio G Rojas-Zambrano
- Augusto R Rojas-Zambrano
- Eduardo A Molina-Varas
Publication Details
- Journal
- Cureus
- Published
- 2026-11-19
- DOI
- https://doi.org/10.7759/cureus.119932
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00